Asset

RILONACEPT

Kiniksa Pharmaceuticals International plc Class A Ordinary Shares

Revenue

No revenue reported in loaded filings.

Clinical trials (2)

NCT IDPhaseStatusStartCompletionSponsor nameTitle
NCT03980522phase2completed2018-01-242019-05-17Kiniksa Pharmaceuticals (UK), Ltd.A Pilot Study of KPL-914 in Recurrent Pericarditis
NCT03737110phase3completed2019-01-072020-05-29Kiniksa Pharmaceuticals (UK), Ltd.Study to Assess the Efficacy and Safety of Rilonacept Treatment in Participants With Recurrent Pericarditis

FDA applications (1)

ApplicationTypeApplicant
BLA 125249BLAKiniksa Pharmaceuticals (UK), Ltd.

Marketed products (1)

  • ARCALYST